Search - tctmd.com

Displaying 601 - 620 of 808

Sort: Relevancy | Date

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

News Conference News TCT 2016

Novel Method of Softening Hard CTO Plaque May Ease Procedural Difficulties

Yael L. Maxwell

November 02, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Industry News

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

October 31, 2016

Presentation TCT 2016

Rationale for and Design of ABSORB IV (Five-Year Results): What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, Davide Capodanno

October 30, 2016

Presentation TCT 2016

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, C. Michael Gibson

October 30, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

Rationale for and Design of ISCHEMIA: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, Bernard J. Gersh

October 30, 2016

Presentation TCT 2016

Rationale for and Design of COMPLETE: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, Anthony H. Gershlick

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Industry News

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

October 30, 2016

News Conference News TCT 2016

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

Todd Neale

October 29, 2016

News Daily News

Fallout From Rehospitalization After Acute MI May Extend Beyond Economics

Yael L. Maxwell

October 28, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Daily News

Ipsilateral Ulnar Compression Significantly Reduces Risk of Radial Artery Occlusion After Transradial PCI

Michael O'Riordan

October 03, 2016

News Conference News ESC 2016

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Todd Neale

September 09, 2016

News Daily News

Patient-Level Data Supports PCI for Some Patients with Unprotected Left Main Disease

Yael L. Maxwell

September 07, 2016

News Conference News ESC 2016

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Michael O'Riordan

August 30, 2016

Advertisement

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

Novel Method of Softening Hard CTO Plaque May Ease Procedural Difficulties

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

Rationale for and Design of ABSORB IV (Five-Year Results): What I Expect the Findings to Be But What Wont Surprise Me!

Rationale for and Design of TWILIGHT and GLOBAL LEADERS: What I Expect the Findings to Be But What Wont Surprise Me!

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Rationale for and Design of ISCHEMIA: What I Expect the Findings to Be But What Wont Surprise Me!

Rationale for and Design of COMPLETE: What I Expect the Findings to Be But What Wont Surprise Me!

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

Fallout From Rehospitalization After Acute MI May Extend Beyond Economics

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Ipsilateral Ulnar Compression Significantly Reduces Risk of Radial Artery Occlusion After Transradial PCI

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Patient-Level Data Supports PCI for Some Patients with Unprotected Left Main Disease

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content